CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ("PNAs") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER

• Main Authors: PAN, DIPANJAN, WELCH, MICHAEL, JOHN, LI, XIAOXU, SUN, XIANKAI, BECKER, MATTHEW, L, ROSSIN, RAFFAELLA, TAYLOR, JOHN-STEPHEN, TURNER, JEFFREY, L, WOOLEY, KAREN, L, FANG, HUAFENG
• Format: Patent
• Language: English; French
• Published: 02.11.2006
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OFSOLID INORGANIC COMPOUNDS; INORGANIC CHEMISTRY; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NANOTECHNOLOGY; PERFORMING OPERATIONS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; SPIRITS; TRANSPORTING; VINEGAR; WINE

A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2'-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50. Cette invention concerne un conjugué de particule biologiquement actif fonctionnel utilisé pour le diagnostic et le traitement du cancer comme point d'entrée biologique et comprenant une particule nanométrique à laquelle un ligand de ciblage intracellulaire est associé, lequel ligand comprend un PNA, ou autre analogue oligonucléotide résistant aux nucléases, tel qu'un ARNm-MOE (ARNm 2'-méthoxyéthyle) ou un LNA (acide nucléique verrouillé), comprenant une séquence qui se lie sélectivement à un ARNm exprimé ou surexprimé de manière unique spécifique du cancer ou d'un état pathologique chez un mammifère vivant. Selon un aspect de cette invention, la cible surexprimée de manière unique spécifique du cancer ou d'un état pathologique est l'ARNm unr qui peut être ciblée par la séquence antisens PNA50.